A Mocroft

Summary

Affiliation: University College London
Country: UK

Publications

  1. ncbi Chronic renal failure among HIV-1-infected patients
    Amanda Mocroft
    Royal Free Centre for HIV Medicine, and Department of Primary Care and Population Sciences, Royal Free and University College Medical Schools, Royal Free Campus, Rowland Hill Street, London, UK
    AIDS 21:1119-27. 2007
  2. ncbi Are specific antiretrovirals associated with an increased risk of discontinuation due to toxicities or patient/physician choice in patients with hepatitis C virus coinfection?
    Amanda Mocroft
    Royal Free Centre for HIV Medicine and Department of Primary Care and Population Sciences, Royal Free and University College Medical School, London, UK
    Antivir Ther 10:779-90. 2005
  3. ncbi Decline in the AIDS and death rates in the EuroSIDA study: an observational study
    A Mocroft
    Royal Free Centre for HIV Medicine and Department of Primary Care and Population Sciences, Royal Free and University College Medical School, London, UK
    Lancet 362:22-9. 2003
  4. ncbi Virological rebound after suppression on highly active antiretroviral therapy
    Amanda Mocroft
    Royal Free Centre for HIV Medicine and Department of Primary Care and Population Sciences, Royal Free and University College Medical School, London, UK
    AIDS 17:1741-51. 2003
  5. ncbi The feasibility of clinical endpoint trials in HIV infection in the highly active antiretroviral treatment (HAART) era
    A Mocroft
    Royal Free Centre for HIV Medicine, Dept Primary Care and Population Sciences, Royal Free and University College Medical School, Royal Free Campus, Rowland Hill St, London NW3 2PF, UK
    Clin Trials 3:119-32. 2006
  6. ncbi Is there evidence for an increase in the death rate from liver-related disease in patients with HIV?
    Amanda Mocroft
    Royal Free Centre for HIV Medicine and Dept Primary Care and Population Sciences, Royal Free and University College Medical School, London, UK
    AIDS 19:2117-25. 2005
  7. ncbi Starting highly active antiretroviral therapy: why, when and response to HAART
    Amanda Mocroft
    Royal Free Centre for HIV Medicine and Department of Primary Care and Population Sciences, Royal Free and University College Medical School, Royal Free Campus, Rowland Hill St, London NW3 2PF, UK
    J Antimicrob Chemother 54:10-3. 2004
  8. ncbi Comparison of single and boosted protease inhibitor versus nonnucleoside reverse transcriptase inhibitor-containing cART regimens in antiretroviral-naïve patients starting cART after January 1, 2000
    - Mocroft
    Department of Primary Care and Population Sciences, Royal Free and University College Medical School, London, United Kingdom
    HIV Clin Trials 7:271-84. 2006
  9. ncbi Time to virological failure of 3 classes of antiretrovirals after initiation of highly active antiretroviral therapy: results from the EuroSIDA study group
    A Mocroft
    Royal Free Centre for HIV Medicine and Department of Primary Care and Population Sciences, Royal Free and University College London Medical Schools, London, United Kingdom
    J Infect Dis 190:1947-56. 2004
  10. ncbi Changes in hospital admissions across Europe: 1995-2003. Results from the EuroSIDA study
    A Mocroft
    Royal Free Centre for HIV Medicine, Royal Free and University College Medical School, London, UK
    HIV Med 5:437-47. 2004

Collaborators

Detail Information

Publications80

  1. ncbi Chronic renal failure among HIV-1-infected patients
    Amanda Mocroft
    Royal Free Centre for HIV Medicine, and Department of Primary Care and Population Sciences, Royal Free and University College Medical Schools, Royal Free Campus, Rowland Hill Street, London, UK
    AIDS 21:1119-27. 2007
    ..The role of exposure to antiretrovirals in chronic renal failure (CRF) is not well understood. Glomerular filtration rates (GFR) are estimated using the Cockcroft-Gault (CG) or Modification of Diet in Renal Disease (MDRD) equations...
  2. ncbi Are specific antiretrovirals associated with an increased risk of discontinuation due to toxicities or patient/physician choice in patients with hepatitis C virus coinfection?
    Amanda Mocroft
    Royal Free Centre for HIV Medicine and Department of Primary Care and Population Sciences, Royal Free and University College Medical School, London, UK
    Antivir Ther 10:779-90. 2005
    ..Little information to address this concern is available from clinical trials as patients with HCV are often excluded...
  3. ncbi Decline in the AIDS and death rates in the EuroSIDA study: an observational study
    A Mocroft
    Royal Free Centre for HIV Medicine and Department of Primary Care and Population Sciences, Royal Free and University College Medical School, London, UK
    Lancet 362:22-9. 2003
    ..Since the introduction of highly active antiretroviral therapy (HAART), little is known about whether changes in HIV-1 mortality and morbidity rates have been sustained. We aimed to assess possible changes in these rates across Europe...
  4. ncbi Virological rebound after suppression on highly active antiretroviral therapy
    Amanda Mocroft
    Royal Free Centre for HIV Medicine and Department of Primary Care and Population Sciences, Royal Free and University College Medical School, London, UK
    AIDS 17:1741-51. 2003
    ..Treatment-naive patients were at a lower risk of rebound, but among drug-experienced patients, those who added new nucleosides had a lower risk of rebound, as were patients with a good immunological response...
  5. ncbi The feasibility of clinical endpoint trials in HIV infection in the highly active antiretroviral treatment (HAART) era
    A Mocroft
    Royal Free Centre for HIV Medicine, Dept Primary Care and Population Sciences, Royal Free and University College Medical School, Royal Free Campus, Rowland Hill St, London NW3 2PF, UK
    Clin Trials 3:119-32. 2006
    ..Cohort studies of patients with HIV can provide key estimates of the likely disease progression, required sample size and follow-up...
  6. ncbi Is there evidence for an increase in the death rate from liver-related disease in patients with HIV?
    Amanda Mocroft
    Royal Free Centre for HIV Medicine and Dept Primary Care and Population Sciences, Royal Free and University College Medical School, London, UK
    AIDS 19:2117-25. 2005
    ..Increases in deaths due to liver-related disease (LRD) among HIV-infected individuals have been reported although the influence of combination antiretroviral therapy (cART) on LRD is controversial...
  7. ncbi Starting highly active antiretroviral therapy: why, when and response to HAART
    Amanda Mocroft
    Royal Free Centre for HIV Medicine and Department of Primary Care and Population Sciences, Royal Free and University College Medical School, Royal Free Campus, Rowland Hill St, London NW3 2PF, UK
    J Antimicrob Chemother 54:10-3. 2004
    ..There has been a switch to more conservative therapy recently, given concerns about toxicities and the difficulties of adhering to a complicated regimen long term...
  8. ncbi Comparison of single and boosted protease inhibitor versus nonnucleoside reverse transcriptase inhibitor-containing cART regimens in antiretroviral-naïve patients starting cART after January 1, 2000
    - Mocroft
    Department of Primary Care and Population Sciences, Royal Free and University College Medical School, London, United Kingdom
    HIV Clin Trials 7:271-84. 2006
    ..Few published studies have considered both the short- and long-term virologic or immunologic response to combination antiretroviral therapy (cART) and the impact of different cART strategies...
  9. ncbi Time to virological failure of 3 classes of antiretrovirals after initiation of highly active antiretroviral therapy: results from the EuroSIDA study group
    A Mocroft
    Royal Free Centre for HIV Medicine and Department of Primary Care and Population Sciences, Royal Free and University College London Medical Schools, London, United Kingdom
    J Infect Dis 190:1947-56. 2004
    ....
  10. ncbi Changes in hospital admissions across Europe: 1995-2003. Results from the EuroSIDA study
    A Mocroft
    Royal Free Centre for HIV Medicine, Royal Free and University College Medical School, London, UK
    HIV Med 5:437-47. 2004
    ....
  11. ncbi Limited but increasing use of treatment for hepatitis C across Europe in patients coinfected with HIV and hepatitis C
    Amanda Mocroft
    Royal Free Centre for HIV Medicine, Department of Primary Care and Population Sciences, Royal Free and University College Medical School, London, UK
    Scand J Infect Dis 38:1092-7. 2006
    ..6 - 6.1) to 32.6 per 1000 PYFU at/after 2004 (95% CI 22.5 - 42.7). Although prescription of HCV therapy is increasing in HIV-coinfected patients, it remains infrequent and variable across regions of Europe...
  12. ncbi Reasons for stopping antiretrovirals used in an initial highly active antiretroviral regimen: increased incidence of stopping due to toxicity or patient/physician choice in patients with hepatitis C coinfection
    A Mocroft
    Royal Free Centre for HIV Medicine and Department of Primary Care and Population Sciences, Royal Free and University College Medical School, London, NW3 2PF UK
    AIDS Res Hum Retroviruses 21:743-52. 2005
    ..Managing adverse events must remain a key intervention in maintaining HAART. There is a need for further studies to describe the relationship between HCV, specific antiretrovirals, and different treatment strategies...
  13. pmc Interruption of antiretroviral therapy is associated with increased plasma cystatin C
    Amanda Mocroft
    University College London Medical School, London, UK
    AIDS 23:71-82. 2009
    ....
  14. ncbi Reasons for stopping antiretrovirals used in an initial highly active antiretroviral regimen: increased incidence of stopping due to toxicity or patient/physician choice in patients with hepatitis C coinfection
    A Mocroft
    Royal Free Centre for HIV Medicine and Department of Primary Care and Population Sciences, Royal Free and University College London Medical Schools, Roayal Free campus, London, UK
    AIDS Res Hum Retroviruses 21:527-36. 2005
    ..Managing adverse events must remain a key intervention in maintaining HAART. There is a need for further studies to describe the relationship between HCV, specific antiretrovirals, and different treatment strategies...
  15. ncbi Risk of discontinuation of nevirapine due to toxicities in antiretroviral-naive and -experienced HIV-infected patients with high and low CD4+ T-cell counts
    Amanda Mocroft
    Royal Free and University College Medical School, London, UK
    Antivir Ther 12:325-33. 2007
    ....
  16. ncbi Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort study
    A Mocroft
    Royal Free and University College Medical School, London, UK
    Lancet 370:407-13. 2007
    ..We aimed to assess whether the CD4 count for patients with maximum virological suppression (viral load <50 copies per mL) continues to increase with long-term cART to reach levels seen in HIV-negative populations...
  17. doi Loss to follow-up in an international, multicentre observational study
    A Mocroft
    Royal Free and University College Medical School, London, UK
    HIV Med 9:261-9. 2008
    ..The aim of this work was to assess loss to follow-up (LTFU) in EuroSIDA, an international multicentre observational cohort study...
  18. doi Regional differences in the risk of triple class failure in European patients starting combination antiretroviral therapy after 1 January 1999
    A Mocroft
    Department of Primary Care and Population Sciences, Royal Free and University College Medical School, London, UK
    HIV Med 9:41-6. 2008
    ..33; 95% CI 0.15-0.74; P=0.0072) or a nonnucleotide reverse transcriptase inhibitor (NNRTI)-based regimen (0.59; 95% CI 0.37-0.94; P=0.026) had a reduced incidence of TCF...
  19. ncbi Short-term clinical disease progression in HIV-1-positive patients taking combination antiretroviral therapy: the EuroSIDA risk-score
    Amanda Mocroft
    Department of Primary Care and Population Sciences, Royal Free and University College Medical School, London, UK
    AIDS 21:1867-75. 2007
    ..To derive and validate a clinically applicable prognostic score for predicting short-term disease progression in HIV-infected patients taking combination antiretroviral therapy (cART)...
  20. ncbi Relationship between antiretrovirals used as part of a cART regimen and CD4 cell count increases in patients with suppressed viremia
    Amanda Mocroft
    Department of Primary Care and Population Sciences, Royal Free and University College Medical School, Royal Free Campus, Rowland Hill Street, London NW3 2PF, UK
    AIDS 20:1141-50. 2006
    ..It is unknown if the CD4 cell count response differs according to antiretroviral drugs used in combination antiretroviral therapy (cART) in patients with maximal virological suppression [viral load (VL) < 50 copies/ml]...
  21. doi Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients
    Amanda Mocroft
    HIV Epidemiology and Biostatistics Group, Research Department of Infection and Population Health, Division of Population Health, University College London Medical School, Royal Free Campus, London, UK
    AIDS 24:1667-78. 2010
    ..Chronic kidney disease (CKD) in HIV-positive persons might be caused by both HIV and traditional or non-HIV-related factors. Our objective was to investigate long-term exposure to specific antiretroviral drugs and CKD...
  22. doi Detection of HIV drug resistance during antiretroviral treatment and clinical progression in a large European cohort study
    Alessandro Cozzi-Lepri
    Research Department of Infection and Population Health, Royal Free and University College Medical School, London, UK
    AIDS 22:2187-98. 2008
    ..To investigate the relationship between detection of HIV drug resistance by 2 years from starting antiretroviral therapy and the subsequent risk of progression to AIDS and death...
  23. ncbi A comparison of exposure groups in the EuroSIDA study: starting highly active antiretroviral therapy (HAART), response to HAART, and survival
    A Mocroft
    Royal Free Centre for HIV Medicine, Royal Free and University College Medical School, London, England
    J Acquir Immune Defic Syndr 22:369-78. 1999
    ..Given the decreased mortality and incidence of AIDS-defining illnesses among patients with HIV who start HAART, this may lead to a poorer prognosis among intravenous drug users...
  24. doi Temporal changes and regional differences in treatment uptake of hepatitis C therapy in EuroSIDA
    D Grint
    University College London, London, UK
    HIV Med 14:614-23. 2013
    ..All HIV/hepatitis C virus (HCV)-coinfected patients with chronic HCV infection and ≥ F2 fibrosis should be considered for HCV therapy. This study aimed to determine the rate of HCV treatment uptake among coinfected patients in Europe...
  25. doi Does less frequent routine monitoring of patients on a stable, fully suppressed cART regimen lead to an increased risk of treatment failure?
    Joanne Reekie
    HIV Epidemiology and Biostatistics Group, Research Department of Infection and Population Health, Royal Free and University College Medical School, London, UK
    AIDS 22:2381-90. 2008
    ..To investigate whether HIV-infected patients on a stable and fully suppressive combination antiretroviral therapy (cART) regimen could safely be monitored less often than the current recommendations of every 3 months...
  26. doi A comparison of the long-term durability of nevirapine, efavirenz and lopinavir in routine clinical practice in Europe: a EuroSIDA study
    J Reekie
    Research Department of Infection and Population Health, University College London Medical School, Royal Free Campus, London, UK
    HIV Med 12:259-68. 2011
    ..The aim of this analysis was to compare the durability of nevirapine, efavirenz and lopinavir regimens based on these measures...
  27. ncbi Changes in AIDS-defining illnesses in a London Clinic, 1987-1998
    A Mocroft
    Department of Primary Care and Population Sciences, Royal Free Centre for HIV Medicine, Royal Free and University College Medical School, University College London, England
    J Acquir Immune Defic Syndr 21:401-7. 1999
    ....
  28. ncbi Gender differences in virologic response to treatment in an HIV-positive population: a cohort study
    A L Moore
    Royal Free Centre for HIV Medicine and Department of Primary Care and Population Sciences, Royal Free and University College Medical School, Hampstead, London, United Kingdom
    J Acquir Immune Defic Syndr 26:159-63. 2001
    ..To establish whether a gender difference in virologic response to highly active antiretroviral treatment (HAART) exists...
  29. doi Serious fatal and nonfatal non-AIDS-defining illnesses in Europe
    Amanda Mocroft
    Research Department of Infection and Population Health, University College Medical School, London, UK
    J Acquir Immune Defic Syndr 55:262-70. 2010
    ..Little is known about the incidence and risk factors for serious non-AIDS-defining events...
  30. doi Transmitted drug resistant HIV-1 and association with virologic and CD4 cell count response to combination antiretroviral therapy in the EuroSIDA Study
    Wendy P Bannister
    Department of Primary Care and Population Sciences, Royal Free and University College Medical School, London, United Kingdom
    J Acquir Immune Defic Syndr 48:324-33. 2008
    ..To investigate prevalence of transmitted drug-resistant human immunodeficiency virus (TDR) and factors associated with TDR and to compare virological and CD4 count response to combination antiretroviral therapy...
  31. ncbi Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group
    A Mocroft
    Royal Free Centre for HIV Medicine and Department of Primary Care and Population Sciences, Royal Free and University College Medical School, University College London, UK
    Lancet 352:1725-30. 1998
    ..We examined the change in these mortality rates of HIV-1-infected patients across Europe during 1994-98, and assessed the extent to which changes can be explained by the use of new therapeutic regimens...
  32. ncbi Virological failure among patients on HAART from across Europe: results from the EuroSIDA study
    A Mocroft
    Royal Free Centre for HIV Medicine, Department of Primary Care and Population Sciences, Royal Free and University College Medical School, London, UK
    Antivir Ther 5:107-12. 2000
    ..To monitor the response to highly active antiretroviral therapy (HAART) over time and the proportions of patients with poor virological control in order to help provide some insight into drug resistance...
  33. doi Stability of hepatitis C virus (HCV) RNA levels among interferon-naïve HIV/HCV-coinfected individuals treated with combination antiretroviral therapy
    D Grint
    HIV Epidemiology and Biostatistics Group, Research Department of Infection and Population Health, University College London Royal Free Campus, London, UK
    HIV Med 14:370-8. 2013
    ..High HCV RNA levels have been associated with poor treatment response. This study aimed to examine the natural history of HCV RNA in chronically HCV/HIV-coinfected individuals...
  34. ncbi Reasons for modification and discontinuation of antiretrovirals: results from a single treatment centre
    A Mocroft
    Department of Primary Care and Populations Sciences, Royal Free Centre for HIV Medicine, Royal Free and University College Medical School, London, UK
    AIDS 15:185-94. 2001
    ..To describe the reasons for, and factors associated with, modification and discontinuation of highly active antiretroviral therapy (HAART) regimens at a single clinic...
  35. doi History of viral suppression on combination antiretroviral therapy as a predictor of virological failure after a treatment change
    J Reekie
    Research Department of Infection and Population Health, University College London Medical School, UK
    HIV Med 11:469-78. 2010
    ..The relationship between such differences and risk of virological failure after starting a new antiretroviral could help with patient monitoring strategies...
  36. doi Rate of accumulation of thymidine analogue mutations in patients continuing to receive virologically failing regimens containing zidovudine or stavudine: implications for antiretroviral therapy programs in resource-limited settings
    Alessandro Cozzi-Lepri
    Research Department of Infection and Population Health, Royal Free and University College Medical School, London, United Kingdom
    J Infect Dis 200:687-97. 2009
    ....
  37. doi Relationship between current level of immunodeficiency and non-acquired immunodeficiency syndrome-defining malignancies
    Joanne Reekie
    University College London Medical School, London, UK
    Cancer 116:5306-15. 2010
    ..However, conflicting data have been reported on the relationship between immunodeficiency and the development of some non-AIDS-defining malignancies...
  38. ncbi Changes in the cause of death among HIV positive subjects across Europe: results from the EuroSIDA study
    A Mocroft
    Royal Free Centre for HIV Medicine, Department of Primary Care and Population Sciences, Royal Free and University College Medical School, London, UK
    AIDS 16:1663-71. 2002
    ..We investigated these changes, patients who died without an AIDS diagnosis and factors relating to pre-AIDS deaths...
  39. ncbi Response to antiretroviral therapy among patients exposed to three classes of antiretrovirals: results from the EuroSIDA study
    A Mocroft
    Royal Free Centre for HIV Medicine, Department of Primary Care and Population Sciences, Royal Free and University College Medical School, London, UK
    Antivir Ther 7:21-30. 2002
    ..Outcomes in people starting salvage regimens appear to depend on the number of new drugs started but not on the total number of drugs being used...
  40. ncbi Are there gender differences in starting protease inhibitors, HAART, and disease progression despite equal access to care?
    A Mocroft
    Royal Free Centre for HIV Medicine, Departments of Primary Care and Population Sciences, Royal Free and University College Medical School, London, UK
    J Acquir Immune Defic Syndr 24:475-82. 2000
    ....
  41. doi Estimating prevalence of accumulated HIV-1 drug resistance in a cohort of patients on antiretroviral therapy
    Wendy P Bannister
    Research Department of Infection and Population Health, University College London Medical School, London, UK
    J Antimicrob Chemother 66:901-11. 2011
    ....
  42. doi A comparison of estimated glomerular filtration rates using Cockcroft-Gault and the Chronic Kidney Disease Epidemiology Collaboration estimating equations in HIV infection
    A Mocroft
    Department of Infection and Population Health, University College London, London, UK
    HIV Med 15:144-52. 2014
    ....
  43. ncbi Brief report: two-year outcome of a multidrug regimen in patients who did not respond to a protease inhibitor regimen
    Mike Youle
    Royal Free Centre for HIV Medicine, Royal Free and University College Medical School, London, United Kingdom
    J Acquir Immune Defic Syndr 29:58-61. 2002
    ..Thus, a substantial proportion of patients who had failed to respond virologically to PI-containing regimens can achieve profound and sustained virologic suppression with a multidrug regimen...
  44. pmc Changes over time in risk factors for cardiovascular disease and use of lipid-lowering drugs in HIV-infected individuals and impact on myocardial infarction
    C A Sabin
    Dept of Primary Care and Population Sciences, Royal Free and UC Medical School, Rowland Hill St, London, NW3 2PF, United Kingdom
    Clin Infect Dis 46:1101-10. 2008
    ..We evaluated changes in risk factors for CVD and the use of lipid-lowering therapy in HIV-infected individuals and assessed the impact of any changes on the incidence of myocardial infarction...
  45. doi CD4 count and viral load specific rates of AIDS, non-AIDS and deaths according to current antiretroviral use
    A Mocroft
    University College London, London, UK
    J Int AIDS Soc 15:18191. 2012
    ....
  46. ncbi Changes in lymphocyte subsets in human immunodeficiency virus-positive persons with < 5 CD4 T lymphocytes/mm3
    C A Sabin
    Department of Primary Care and Population Sciences, Royal Free Hospital and School of Medicine, London, United Kingdom
    J Infect Dis 178:1166-9. 1998
    ..Despite almost a complete absence of CD4 T lymphocytes, lymphocyte subset monitoring is useful in identifying decreasing CD8 T lymphocyte levels that predict short-term prognosis...
  47. ncbi Causes of death in HIV infection: the key determinant to define the clinical response to anti-HIV therapy
    Amanda Mocroft
    Royal Free Centre for HIV Medicine and Department of Primary Care and Population Sciences, Royal Free and University College Medical School, London, UK
    AIDS 18:2333-7. 2004
    ..Compared with homosexual individuals, IDU had an increased incidence of new AIDS/death, but only for non-HIV deaths. There is an urgent need to define and standardize causes of death in observational studies...
  48. ncbi The changing pattern of Kaposi sarcoma in patients with HIV, 1994-2003: the EuroSIDA Study
    Amanda Mocroft
    Royal Free Centre for HIV Medicine, Royal Free and University College Medical School, London, United Kingdom
    Cancer 100:2644-54. 2004
    ....
  49. ncbi Decline in esophageal candidiasis and use of antimycotics in European patients with HIV
    Amanda Mocroft
    Royal Free Centre for HIV Medicine and Dept Primary Care and Population Sciences, Royal Free and University College Medical School, London, United Kingdom
    Am J Gastroenterol 100:1446-54. 2005
    ....
  50. doi Impact of antiretroviral therapy (ART), immunosuppression and viraemia on lipid levels: the D:A:D study
    D Kamara
    University College London, Infection and Population Health, London, UK
    J Int AIDS Soc 15:18280. 2012
    ..The higher TC/TG and lower HDL-C levels seen among those with low nadir CD4 count and with a prior AIDS diagnosis suggests severe immunosuppression may be associated with dyslipidaemia over the long-term...
  51. ncbi Reduced bone mineral density in HIV-positive individuals
    A L Moore
    Centre for HIV Medicine, Royal Free Hospital, London, UK
    AIDS 15:1731-3. 2001
    ..Our results suggest a possible association between PI and reduced BMD, and further complicate the debate regarding when to commence treatment of HIV and with what agents to start...
  52. doi Temporal changes and regional differences in treatment uptake of hepatitis C therapy in EuroSIDA
    D Grint
    UCL Royal Free Campus, Research Department of Infection and Population Health, London, UK
    J Int AIDS Soc 15:18118. 2012
    ..HCV treatment was not associated with all-cause or liver-related death in this population...
  53. ncbi Assessing the cost-effectiveness of HAART for adults with HIV in England
    A H Miners
    Royal Free Centre for HIV Medicine, Department of Primary Care and Population Sciences, Royal Free and University College Medical School, London, UK
    HIV Med 2:52-8. 2001
    ..To assess the cost-effectiveness of highly active antiretroviral therapy (HAART) compared with two nucleoside reverse transcriptase inhibitors (NRTIs) for HIV infected individuals...
  54. ncbi Shorter survival in HIV-positive patients with diarrhoea who excrete adenovirus from the GI tract
    C A Sabin
    Department of Primary Care and Population Sciences, Royal Free and University College Medical School, London, England
    J Med Virol 58:280-5. 1999
    ..Gastrointestinal adenovirus excretion occurs at an advanced stage of HIV disease, and is associated with a poor prognosis. We suggest that adenoviruses may contribute to mortality in this population...
  55. ncbi Incidence of abacavir hypersensitivity reactions in euroSIDA
    Wendy P Bannister
    Royal Free and University College Medical School, London, UK
    Antivir Ther 13:687-96. 2008
    ..The aim of the study was to investigate the incidence of abacavir-related hypersensitivity reaction (HSR) and associated deaths in EuroSIDA HIV-1-infected patients...
  56. doi Estimated average annual rate of change of CD4(+) T-cell counts in patients on combination antiretroviral therapy
    Amanda Mocroft
    Research Department of Infection and Population Health, University College London Medical School, London, UK
    Antivir Ther 15:563-70. 2010
    ..Patients receiving combination antiretroviral therapy (cART) might continue treatment with a virologically failing regimen. We sought to identify annual change in CD4(+) T-cell count according to levels of viraemia in patients on cART...
  57. ncbi HIV-1 subtypes and response to combination antiretroviral therapy in Europe
    Wendy P Bannister
    Department of Primary Care and Population Sciences, Royal Free and University College Medical School, London, UK
    Antivir Ther 11:707-15. 2006
    ..Antiretroviral drugs have predominantly been developed in Western Europe/North America on the basis of the most prevalent subtype, B. However, non-B subtypes are increasingly spreading worldwide...
  58. doi Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA
    Wendy P Bannister
    Department of Primary Care and Population Sciences, Royal Free and University College Medical School, London, UK
    AIDS 22:367-76. 2008
    ..To compare virological outcome and genotypic resistance profiles in HIV-1-infected patients starting non-nucleoside reverse transcriptase inhibitor (NNRTI)-containing regimens...
  59. ncbi The role of antiretroviral therapy in the incidence of pancreatitis in HIV-positive individuals in the EuroSIDA study
    Colette J Smith
    Royal Free and University College Medical School, London, UK
    AIDS 22:47-56. 2008
    ..This study investigated the incidence of pancreatitis and its association with antiretroviral therapy (ART), focussing on stavudine and didanosine...
  60. ncbi Regional changes over time in initial virologic response rates to combination antiretroviral therapy across Europe
    Wendy P Bannister
    Department of Primary Care and Population Sciences, Royal Free and University College Medical School, London, UK
    J Acquir Immune Defic Syndr 42:229-37. 2006
    ..Regional variations may identify differences in available antiretroviral drugs or patient management...
  61. pmc Death rates in HIV-positive antiretroviral-naive patients with CD4 count greater than 350 cells per microL in Europe and North America: a pooled cohort observational study
    Rebecca K Lodwick
    HIV Epidemiology and Biostatistics Group, Research Department of Infection and Population Health, UCL Medical School, Royal Free Campus, London, UK
    Lancet 376:340-5. 2010
    ..We aimed to examine this by analysis of pooled data from industrialised countries...
  62. ncbi Highly active antiretroviral therapy and cervical intraepithelial neoplasia
    Antonia L Moore
    Center for HIV Medicine, Royal Free Hospital, London, UK
    AIDS 16:927-9. 2002
    ..Such studies will provide the basis for guidelines for monitoring CIN in HIV-positive women in the HAART era...
  63. ncbi Age related trends in the incidence of endometrial cancer in South East England 1962-1997
    G Somoye
    Chase Farm Barnet Hospital Trust, London, UK
    J Obstet Gynaecol 25:35-8. 2005
    ..The increased incidence in women aged 85 and over have potential implications for the planning and provision of cancer services in the future...
  64. ncbi Predictors of immunological failure after initial response to highly active antiretroviral therapy in HIV-1-infected adults: a EuroSIDA study
    Ulrik Bak Dragsted
    Hvidovre University Hospital, Copenhagen, Denmark
    J Infect Dis 190:148-55. 2004
    ..Factors that determine the immunological response to highly active antiretroviral therapy (HAART) are poorly defined...
  65. ncbi HIV survival benefit associated with earlier antiviral therapy
    Amanda Mocroft
    Ann Intern Med 140:578-9; author reply 579. 2004
  66. ncbi Changing incidence of central nervous system diseases in the EuroSIDA cohort
    Antonella d'Arminio Monforte
    Institute of Infectious and Tropical Diseases, University of Milan, I Sacco Hospital, Via GB Grassi 74, 20157 Milan, Italy
    Ann Neurol 55:320-8. 2004
    ....
  67. doi Incidence of pancreatitis in HIV-infected patients, and the association with antiretroviral therapy
    Colette J Smith
    AIDS 22:997-8. 2008
  68. ncbi Anemia and survival in human immunodeficiency virus
    Jens D Lundgren
    Copenhagen HIV Programme 044, Hvidovre University Hospital, Hvidovre, Denmark
    Clin Infect Dis 37:S297-303. 2003
    ..5-20.1), respectively, compared with patients with no anemia. The mechanisms underlying why hemoglobin is such a strong prognostic marker and whether correction of anemia itself results in a better prognosis remain to be determined...
  69. ncbi Association of virus load, CD4 cell count, and treatment with clinical progression in human immunodeficiency virus-infected patients with very low CD4 cell counts
    Veronica Miller
    Klinikum der Johann Wolfgang Goethe Universitat, Zentrum der Inneren Medizin, Frankfurt, Germany
    J Infect Dis 186:189-97. 2002
    ..10, P<.0001, respectively, for 4, 3, 2, 1, or no drugs vs. >or=5 drugs). Although reverse causality cannot be excluded, more intense antiviral treatment appears to decrease the risk of progression in immunocompromised patients...
  70. ncbi A clinically prognostic scoring system for patients receiving highly active antiretroviral therapy: results from the EuroSIDA study
    Jens D Lundgren
    EuroSIDA Copenhagen HIV Programme Coordinating Centre, Dept of Infectious Diseases, Hvidovre University Hospital, 2650 Hvidovre, Denmark
    J Infect Dis 185:178-87. 2002
    ..38; 95% confidence interval, 1.33-1.43; P<.0001). The scoring system was validated with remarkably good agreement in the 2 other cohorts. This system can be used in patient and resource management...
  71. ncbi [Decline in AIDS and death rates in the EuroSIDA study. An observational study]
    Ole Kirk
    H S Hvidovre Hospital, Copenhagen HIV Programme
    Ugeskr Laeger 166:2572-6. 2004
  72. ncbi Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort
    Deborah Konopnicki
    Division of Infectious Diseases, Saint Pierre University Hospital, Brussels, Belgium
    AIDS 19:593-601. 2005
    ..Whether hepatitis B (HBV) coinfection affects outcome in HIV-1-infected patients remains unclear...
  73. ncbi Current hemoglobin levels are more predictive of disease progression than hemoglobin measured at baseline in patients receiving antiretroviral treatment for HIV type 1 infection
    Justyna D Kowalska
    Hospital for Infectious Diseases, Warsaw, Poland
    AIDS Res Hum Retroviruses 23:1183-8. 2007
    ..30-1.42; p < 0.001). Starting cART was associated with an increase in hemoglobin levels. Lower hemoglobin values, particularly the latest measured, were associated with an increased risk of disease progression...
  74. ncbi Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy
    Jurgen K Rockstroh
    Department of Medicine I, University Hospital Bonn, Bonn, Germany
    J Infect Dis 192:992-1002. 2005
    ....
  75. ncbi The impact of antiretroviral therapy on AIDS and survival
    Jens D Lundgren
    Hvidovre University Hospital, Denmark
    J HIV Ther 11:36-8. 2006
  76. ncbi Impact of HIV-1 reverse transcriptase polymorphism F214L on virological response to thymidine analogue-based regimens in antiretroviral therapy (ART)-naive and ART-experienced patients
    Francesca Ceccherini-Silberstein
    Department of Experimental Medicine, University of Rome Tor Vergata, Rome, Italy
    J Infect Dis 196:1180-90. 2007
    ..A negative association between the polymorphism F214L and type 1 thymidine analogue (TA) mutations (TAMs) has been observed. However, the virological response to TAs according to the detection of F214L has not been evaluated...
  77. pmc Tuberculosis after initiation of antiretroviral therapy in low-income and high-income countries
    Martin W G Brinkhof
    Institute of Social and Preventive Medicine ISPM, University of Berne, Finkenhubelweg 11, CH 3012 Bern, Switzerland
    Clin Infect Dis 45:1518-21. 2007
    ..48 (95% confidence interval, 0.36-0.64) in low-income countries and 0.36 (95% confidence interval, 0.26-0.50) in high-income countries. A low CD4 cell count at the start of therapy was the most important risk factor in both settings...
  78. doi Response to combination antiretroviral therapy: variation by age
    Caroline A Sabin
    AIDS 22:1463-73. 2008
    ..To provide information on responses to combination antiretroviral therapy in children, adolescents and older HIV-infected persons...
  79. ncbi Factors associated with the development of opportunistic infections in HIV-1-infected adults with high CD4+ cell counts: a EuroSIDA study
    Daria Podlekareva
    Hvidovre University Hospital, Kettegaard Alle 30, DK 2650 Hvidovre, Denmark
    J Infect Dis 194:633-41. 2006
    ..Limited data exist on factors predicting the development of opportunistic infections (OIs) at higher-than-expected CD4(+) cell counts in human immunodeficiency virus (HIV) type 1-infected adults...